$CRIS 🚀 +60% 🔹 Curis is a clinical-stage biotech developing targeted cancer therapies, led by its IRAK4 inhibitor emavusertib 🧬 🔹 Huge move today putting th

$CRIS 🚀 +60% 🔹 Curis is a clinical-stage biotech developing targeted cancer therapies, led by its IRAK4 inhibitor emavusertib 🧬 🔹 Huge move today putting this small-cap biotech back on traders' radar 👀 🔹 Clinical milestones and pipeline progress continue to be the key drivers for this name 📈 …